HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. The company employs 1,796 full-time employees The company went IPO on 2006-05-19. The firm operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
The most recent EPS for HUTCHMED (China) Limited is $, expectations of $.
How did HUTCHMED (China) Limited HCM's revenue perform in the last quarter?
HUTCHMED (China) Limited revenue for the last quarter is $
What is the revenue estimate for HUTCHMED (China) Limited?
According to of Wall street analyst, the revenue estimate of HUTCHMED (China) Limited range from $ to $
What's the earning quality score for HUTCHMED (China) Limited?
HUTCHMED (China) Limited has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does HUTCHMED (China) Limited report earnings?
HUTCHMED (China) Limited next earnings report is expected in 2026-06-03
What are HUTCHMED (China) Limited's expected earnings?
HUTCHMED (China) Limited expected earnings is $, according to wall-street analysts.
Did HUTCHMED (China) Limited beat earnings expectations?
HUTCHMED (China) Limited recent earnings of $ expectations.